IRIS
ATZENI, Fabiola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 8.250
NA - Nord America 7.859
AS - Asia 5.879
SA - Sud America 2.382
AF - Africa 219
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 8
Totale 24.608
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.684
RU - Federazione Russa 5.016
SG - Singapore 2.657
BR - Brasile 2.040
CN - Cina 1.375
IE - Irlanda 1.242
HK - Hong Kong 711
SE - Svezia 638
IT - Italia 399
VN - Vietnam 304
FR - Francia 281
DE - Germania 195
IN - India 142
AR - Argentina 124
PL - Polonia 106
GB - Regno Unito 104
BD - Bangladesh 93
IQ - Iraq 80
MX - Messico 72
ZA - Sudafrica 68
TR - Turchia 64
CA - Canada 55
NL - Olanda 54
FI - Finlandia 46
UZ - Uzbekistan 46
EC - Ecuador 45
PK - Pakistan 44
JP - Giappone 41
VE - Venezuela 41
ID - Indonesia 38
CO - Colombia 32
AT - Austria 31
MA - Marocco 28
EG - Egitto 27
UA - Ucraina 27
PY - Paraguay 26
SA - Arabia Saudita 25
BE - Belgio 23
CL - Cile 23
JO - Giordania 22
KE - Kenya 22
BO - Bolivia 21
ES - Italia 20
AE - Emirati Arabi Uniti 19
KZ - Kazakistan 18
PE - Perù 18
IL - Israele 17
NP - Nepal 17
AZ - Azerbaigian 16
DZ - Algeria 16
PH - Filippine 15
TN - Tunisia 15
IR - Iran 14
KG - Kirghizistan 12
PA - Panama 12
LB - Libano 11
OM - Oman 11
PS - Palestinian Territory 10
UY - Uruguay 10
DO - Repubblica Dominicana 9
MY - Malesia 9
QA - Qatar 9
SN - Senegal 9
SY - Repubblica araba siriana 8
TH - Thailandia 8
AL - Albania 7
BY - Bielorussia 7
CI - Costa d'Avorio 7
ET - Etiopia 7
PT - Portogallo 7
AM - Armenia 6
CZ - Repubblica Ceca 6
EU - Europa 6
JM - Giamaica 6
AO - Angola 5
AU - Australia 5
BH - Bahrain 5
CH - Svizzera 5
CR - Costa Rica 5
GE - Georgia 5
KR - Corea 5
RO - Romania 5
DK - Danimarca 4
NI - Nicaragua 4
TW - Taiwan 4
BG - Bulgaria 3
CY - Cipro 3
GA - Gabon 3
GR - Grecia 3
GT - Guatemala 3
HN - Honduras 3
LT - Lituania 3
MN - Mongolia 3
NG - Nigeria 3
RS - Serbia 3
TT - Trinidad e Tobago 3
BN - Brunei Darussalam 2
CG - Congo 2
EE - Estonia 2
HR - Croazia 2
Totale 24.567
Salva come PNG Salva come JPEG
Città #
Moscow 1.751
Singapore 1.523
Dublin 1.240
Ashburn 1.124
Chandler 1.009
Dallas 906
Hong Kong 703
Beijing 572
Nyköping 456
New York 336
Princeton 271
Jacksonville 250
Dearborn 245
The Dalles 230
Medford 229
Lauterbourg 214
Des Moines 203
São Paulo 172
Cambridge 166
San Jose 162
Los Angeles 157
Redondo Beach 116
Buffalo 101
Ho Chi Minh City 101
Warsaw 99
Messina 96
Rio de Janeiro 85
Ann Arbor 74
Munich 70
Hanoi 66
Tianjin 60
Belo Horizonte 59
Frankfurt am Main 59
Pune 59
Wilmington 59
Santa Clara 56
Orem 52
Guangzhou 50
Nanjing 43
Tashkent 42
Shenyang 40
Tokyo 39
Jinan 33
Council Bluffs 32
Baghdad 30
Nuremberg 30
Brasília 28
Johannesburg 28
Milan 28
Porto Alegre 28
Seattle 27
Brooklyn 26
Buenos Aires 25
Amsterdam 24
Campinas 24
London 24
Boardman 23
Shanghai 23
Chennai 22
Falls Church 21
Mexico City 21
Montreal 21
Rome 21
Turku 21
Brussels 20
Salvador 20
Curitiba 19
San Francisco 19
San Mateo 19
Amman 18
Catania 18
Haikou 18
Hebei 18
Nairobi 18
Ningbo 18
Cape Town 17
Dhaka 17
Fortaleza 17
Vienna 17
Zhengzhou 17
Caxias do Sul 16
Guarulhos 16
Phoenix 16
Atlanta 15
Guayaquil 15
Norwalk 15
Quito 15
Aracaju 14
Baku 14
Caracas 14
Dong Ket 14
Hangzhou 14
Istanbul 14
Santo André 14
Asunción 13
Belém 13
Changsha 13
Haiphong 13
Lahore 13
Nanchang 13
Totale 14.479
Salva come PNG Salva come JPEG
Nome #
CORRELATION BETWEEN DISEASE ACTIVITY AND CARDIOVASCULAR PARAMETERS IN PATIENTS WITH ANKYLOSING SPONDYLITIS 192
Adverse events, clinical considerations and management recommendations in rheumatoid arthritis patients treated with JAK inhibitors 191
CARDIOVASCULAR EVALUATION USING NON-INVASIVE IMAGING METHODS IN PATIENTS WITH ANKYLOSING SPONDYLITIS BEFORE AND AFTER 12 MONTHS OF TREATMENT WITH ANTI-TNF DRUGS 183
Algo-dysfunctional syndromes: a critical digest of the recent literature 182
A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis 175
Certainties and uncertainties concerning the contribution of pericytes to the pathogenesis of systemic sclerosis 172
Anti-tumour necrosis factor-α antibodies and B cell homeostasis in human inflammatory bowel diseases 168
Central nervous system involvement in rheumatoid arthritis patients and the potential implications of using biological agents 162
Biomarkers in Rheumatoid Arthritis 158
BODY MASS INDEX, SMOKING STATUS AND RESPONSE TO RITUXIMAB IN RHEUMATOID ARTHRITIS: A REAL-LIFE STUDY. 155
A Review of Chronic Musculoskeletal Pain: Central and Peripheral Effects of Diclofenac 153
Cancer risk and tumour necrosis factor inhibitors in patients with inflammatory arthritis 152
Accelerated subcutaneous nodulosis in patients with rheumatoid arthritis treated with tocilizumab: A case series 147
A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data 145
Recurrent intracranial hemorrhage and cerebral venous sinus thrombosis: an atypical case of Neuro-Behçet’s Syndrome 144
Assessment of enthesis in patients with psoriatic arthritis and fibromyalgia using clinical examination and ultrasound 143
CLINICAL AND ULTRASONOGRAPHIC EVALUATION IN A COHORT OF SUSTAINED REMISSION RHEUMATOID ARTHRITIS PATIENTS AFTER STOPPING BIOLOGIC THERAPY: A SINGLE CENTER EXPERIENCE , 142
Safety Profile of Biologics Used in Rheumatology: An Italian Prospective Pharmacovigilance Study 141
Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: A one-year prospective study 136
An update on emerging drugs for fibromyalgia treatment 134
Anti-adalimumab and anti-certolizumab antibodies titers after discontinuation of adalimumab: Two case reports 133
A proteinuria cut-off level of 0.7 g /day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: Data from the MAINTAIN Nephritis Trial 132
A possible link between ankylosing spondylitis and periodontitis: A systematic review and meta-analysis 128
B Lymphocyte intestinal homing in inflammatory bowel disease 126
The microbiome in connective tissue diseases and vasculitides: An updated narrative review 126
RELATIONSHIP BETWEEN ULTRASONOGRAPHIC SALIVARY GLANDS ABNORMALITIES AND SUBCLINICAL CARDIOVASCULAR INVOLVEMENT IN PATIENTS WITH PRIMARY SJÖGREN SYNDROME 124
The neuropathic pain features in Psoriatic Arthritis: a cross-sectional evaluation of prevalence and associated factors 124
A Proposed Serum Calprotectin IgG Cut-Off Level for Diagnosing Inflammatory Arthritis 123
Biological agents in rheumatoid arthritis: A cross-link between immune tolerance and immune surveillance 123
Are the ACR 2010 diagnostic criteria for fibromyalgia better than the 1990 criteria? 122
Cross Cultural Adaptation and Validation of Italian Version of the Leeds Assessment of Neuropathic Symptoms and Signs Scale and Pain DETECT Questionnaire for the Distinction between Nociceptive and Neuropathic Pain 121
Correlations between immunogenicity, drug levels, and disease activity in an Italian cohort of rheumatoid arthritis patients treated with tocilizumab 120
MEASUREMENT OF SERUM ALPHA-KLOTHO IN SYSTEMIC SCLEROSIS PATIENTS: RESULTS FROM A PIVOTAL STUDY. 119
Retrospective evaluation of patient profiling and effectiveness of apremilast in an Italian multicentric cohort of psoriatic arthritis patients 118
An open, randomized comparison study of cyclosporine A, cyclosporine A + methotrexate and cyclosporine A + hydroxychloroquine in the treatment of early severe rheumatoid arthritis 117
Subclinical atherosclerosis and history of cardiovascular events in Italian patients with rheumatoid arthritis 116
From autoinflammation to autoimmunity: old and recent findings 116
Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry 114
One year in review 2019: fibromyalgia 113
Failure of anti-TNF treatment in patients with rheumatoid arthritis: The pros and cons of the early use of alternative biological agents 112
Systemic rheumatic diseases: from biological agents to small molecules 111
Safety of Abatacept in Rheumatoid Arthritis with Serologic Evidence of Past or Present Hepatitis B Virus Infection 110
Measuring psoriatic disease in clinical practice. An expert opinion position paper 109
PLA1/A2 polymorphism of the platelet glycoprotein receptors IIIA in Behçet's disease 108
Noninvasive imaging methods for evaluating cardiovascular involvement in patients with rheumatoid arthritis before and after anti-TNF drug treatment 107
Longterm retention of tumor necrosis factor-α inhibitor therapy in a large Italian cohort of patients with rheumatoid arthritis from the GISEA Registry: An appraisal of predictors 106
Safety of Abatacept in Italian Patients with Rheumatoid Arthritis and Interstitial Lung Disease: A Multicenter Retrospective Study 106
Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction. 106
Immunogenicity and autoimmunity during anti-TNF therapy 105
TNF inhibitors in rheumatoid arthritis and spondyloarthritis: Are they the same? 105
Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: Results from the GISEA register 105
Cardiovascular risk in ankylosing spondylitis and the effect of anti-TNF drugs: a narrative review 104
Paradoxical Expansion of Th1 and Th17 Lymphocytes in Rheumatoid Arthritis Following Infliximab Treatment: a Possible Explanation for a Lack of Clinical Response 103
Anti-citrullinated peptide antibodies and rheumatoid factor isotypes in the diagnosis of rheumatoid arthritis: An assessment of combined tests 102
CC chemokine receptor 5 polymorphism in Italian patients with Beḩet's disease 101
Ultrasonographyc Evaluation of Metacarpophalangeal Joints Can be Useful in the Differential Diagnosis of Early Rheumatoid Arthritis and Early Spondyloarthritis. A Monocentric Preliminary Study 101
Hyperbaric oxygen treatment of fibromyalgia: a prospective observational clinical trial 101
Retrotransposons shuttling genetic and epigenetic information from the nuclear to the mitochondrial compartment: Do they play a pathogenetic role in scleroderma? 100
How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: analysis of 10,500 patients (Sjögren Big Data Project) 100
Impaired lung transfer factor in fibromyalgia syndrome 100
EULAR recommendations for management of fibromyalgia 100
What are the dangers of biological therapy discontinuation or dose reduction strategies when treating rheumatoid arthritis? 99
Co-Occurrence and Characteristics of Patients With Axial Spondyloarthritis Who Meet Criteria for Fibromyalgia: Results From a UK National Register 99
Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: Real-life data from the LORHEN registry 98
EULAR revised recommendations for the management of fibromyalgia 98
Psoriatic arthritis: From pathogenesis to pharmacologic management 98
Differential Diagnosis of Vasovagal Syncope: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. 98
Chronic widespread pain in the spectrum of rheumatological diseases 97
Efficacy of Cannabis Flos in Patients with Fibromyalgia: A Monocentric 97
EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update 96
Measurement of Serum Klotho in Systemic Sclerosis 96
Pain in systemic sclerosis 96
Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry 96
Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment 96
Efficacy and Safety of Biosimilar and Originator Etanercept in Rheumatoid Arthritis Patients: Real-Life Data 96
Repeat kidney biopsies fail to detect differences between azathioprine and mycophenolate mofetil maintenance therapy for lupus nephritis: data from the MAINTAIN Nephritis Trial 95
AxSpA patients who also meet criteria for fibromyalgia: identifying distinct patient clusters using data from a UK national register (BSRBR-AS) 95
Prescribing motivations and patients’ characteristics related to the use of biologic drugs in adult-onset Still’s disease: analysis of a multicentre “real-life” cohort 95
Malar rash is a predictor of subclinical airway inflammation in patients with systemic lupus erythematosus: a pilot study 94
PREVALENCE OF CHRONIC WIDESPREAD PAIN IN SSC PATIENTS: PRELIMINARY DATA 94
Infections and Biological Therapy in Patients with Rheumatic Diseases 93
DOSE REDUCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS RESPONDING TO THE STANDARD RITUXIMAB REGIMEN. 93
Patients Failing to Fulfill 2016 Criteria for Fibromyalgia Represent a Truly Different Population Subset 93
SDAI AS PREDICTOR OF 1-YEAR EFFICACY OF THE FIRST TNF BLOCKER IN CLINICAL PRACTICE. 92
The profiling of axial spondyloarthritis patient candidate to a biologic therapy: Consensus from a Delphi-panel of Italian experts 92
Study of entheses in patients with spondyloarthritis and inflammatory bowel disease with and without fibromyalgia: The importance of ultrasonography 92
Identification of the clinical features distinguishing psoriatic arthritis and fibromyalgia 91
Cardiovascular Imaging Techniques in Systemic Rheumatic Diseases 91
Adding medical cannabis to standard analgesic treatment for fibromyalgia: a prospective observational study 91
Abnormalities of cardiovascular neural control and reduced orthostatic tolerance in patients with primary fibromyalgia 90
Laboratory monitoring of biological therapies in rheumatology: The role of immunogenicity 90
Efficacy of cyclophosphamide in treating connective tissue disease-related interstitial lung diseases 88
The effect of drugs used in rheumatology for treating SARS-CoV2 infection 88
Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren’s syndrome at diagnosis in 8310 patients: A cross-sectional study from the Big Data Sjögren’s Project Consortium 88
Web/Internet-based telemonitoring of a randomized controlled trial evaluating the time-integrated effects of a 24-week multicomponent intervention on key health outcomes in patients with fibromyalgia 87
Do DMARDs and biologic agents protect from cardiovascular disease in patients with inflammatory arthropathies? 87
Controlled-release pregabalin in the treatment of fibromyalgia 86
Rheumatic diseases and autoimmune vascular dementia 86
Serum klotho concentrations inversely correlate with the severity of nailfold capillaroscopic patterns in patients with systemic sclerosis 86
The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: Results of an italian multicentre study 85
Totale 11.414
Salva come PNG Salva come JPEG
Categoria #
all - tutte 98.047
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 98.047
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021111 0 0 0 0 0 0 0 0 0 47 47 17
2021/20221.179 9 60 3 30 96 21 27 51 36 55 169 622
2022/20233.443 311 221 155 315 169 347 19 199 1.556 14 110 27
2023/20241.113 94 133 188 83 69 383 7 33 4 32 7 80
2024/20254.812 74 44 93 294 148 152 146 1.060 1.340 335 395 731
2025/202612.494 484 947 1.149 759 1.131 3.036 1.653 1.444 1.375 516 0 0
Totale 25.246